论文部分内容阅读
为了观察骨巨细胞瘤刮除术后局部应用几丁糖阿霉素缓释药粒的疗效及全身反应，对４例骨巨细胞瘤刮除术后残腔应用４倍于常规静脉阿霉素用量的几丁糖阿霉素缓释药粒，检测术后１，２及５天血浆中阿霉素含量，以及术后１周、１个月及６个月的肝肾功能。结果表明，术后１，２及５天血浆中阿霉素含量分别为（１４３．０５±２７．５５）ｎｇ／ｍｌ、（５２．１７±１１．２８）ｎｇ／ｍｌ及（４．２５±３．０７）ｎｇ／ｍｌ，术后１周、１个月及６个月的肝肾功能均正常。随访７个月～１９个月，无局部复发、全身反应及Ｘ线片复发表现。认为，几丁糖阿霉素缓释药粒用于骨巨细胞瘤刮除术后是安全、有效的。
In order to observe the efficacy and systemic response of topical application of chitosan adriamycin sustained-release granules after curettage of giant cell tumor of bone, 4 cases of conventional venous doxorubicin were applied to the residual cavity of 4 patients with giant cell tumor of bone. The amount of chitosan adriamycin sustained-release drug particles was used to detect the plasma adriamycin levels on postoperative days 1, 2 and 5, and the liver and kidney function at 1 week, 1 month and 6 months after operation. The results showed that the plasma adriamycin levels were (143.05±27.55) ng/ml, (52.17±11.28) ng/ml, and (4.25±) on postoperative days 1, 2 and 5, respectively. 3.07)ng/ml, liver and kidney function were normal at 1 week, 1 month and 6 months after operation. Followed up for 7 months to 19 months, no local recurrence, systemic reaction and X-ray film recurrence. It is believed that the chitosan adriamycin sustained-release drug particle is safe and effective after the curettage of giant cell tumor of bone.